Famotidine to prevent ASA-associated ulcers

In this manufacturer-funded trial, 404 patients starting ASA (dose range 75mg-325mg) underwent baseline and 12-week endoscopy, and were randomized to placebo or famotidine 20mg BID. At 12 weeks, the famotidine group had significantly fewer gastric ulcers (3% vs 15%), duodenal ulcers (1% vs 9%), and erosive esophagitis (4% vs 19%) compared to placebo. Famotidine is an effective strategy to prevent ASA-associated ulcers/esophagitis (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

1 Comment

  1. Daniel Capurro on July 27, 2009 at 1:05 pm

    Considering that patients were endoscopically screened at the end of the study, looking for the presence of esophageal, gastric and duodenal mucosa alterations, there is a considerable possibility that the investigators diagnosed clinically non-significant complications. This study looks very well designed but it shouldn’t be used yet to guide clinical decisions. Clinicians should wait for a study powered to detect clinically significant complications.

    Daniel Capurro, MD.

Leave a Comment